AdultCHF 10.00
Explore the past, present, and future of medicine at this dedicated learning space, featuring the interactive Wonders of Medicine exhibition and a striking zero-energy media facade.
A collaborative learning, event, and science exhibition space in Basel exploring medicine, health science, and future healthcare innovations.
Located in Basel, the Novartis Pavillon is a public learning and exhibition space dedicated to the science of healthcare. The venue features the interactive Wonders of Medicine exhibition, taking visitors on a journey from laboratory research to patient care. Architecturally, the building is notable for its zero-energy media facade, which uses solar-powered LED cores to project digital art.
The Novartis Pavillon is situated on St. Johanns-Hafen-Weg in the St. Johann neighborhood of Basel. Located on the Novartis Campus, this public learning and science exhibition space serves as an inviting hub for exploring healthcare innovations. Its accessible location within the Basel-Stadt region makes it a convenient destination for visitors planning to explore the city's scientific heritage.
St. Johanns-Hafen-Weg 5
4056 Basel
St. Johann, Basel-Stadt, CH
When planning a visit to the Novartis Pavillon in Basel's St. Johann neighborhood, making a reservation in advance is highly recommended. This public exhibition and event center recommends booking ahead to secure your preferred entry window. Visitors should prepare for an educational experience focused on scientific research and healthcare development.
The Novartis Pavillon in Basel offers an immersive look into healthcare and medical science. Inside, the Wonders of Medicine exhibition features interactive learning stations that walk visitors through the journey from laboratory research to patient treatment. The venue is also notable for its striking architecture, highlighted by a zero-energy media facade with over 30,000 solar-powered LED cores projecting digital art at night. Combining science, art, and design, this learning space provides an educational experience complemented by an on-site café.
An interactive journey through human health and biology.
Learn about pharmaceutical innovation and the future of healthcare through hands-on multimedia displays. This permanent exhibition features personal patient narratives, expert-led scientific content, and a historical overview of Basel's medical history.
Wonders of Medicine
Novartis R&D leaders share insights into the next decade of scientific advancement across oncology, neuroscience, and immunology. This update highlights the innovative platforms and strategies being deployed to address complex patient needs and improve long-term health outcomes.
Novartis has achieved a major milestone with the FDA's traditional approval of Fabhalta (iptacopan) for treating primary IgA nephropathy. This breakthrough medication, which works by targeting the alternative complement pathway, has shown a significant ability to slow the decline of kidney function in adult patients. This development highlights ongoing progress in nephrology and the future of targeted medical research.
Celebrating the 30th anniversary of the Novartis merger, this retrospective looks back on a legacy spanning 250 years of scientific discovery. Discover how a commitment to reimagining medicine continues to drive breakthroughs in healthcare and patient treatment today.
Novartis has announced a strategic agreement to acquire the UK-based biotechnology company Myricx Bio. This partnership aims to advance next-generation antibody-drug conjugate (ADC) therapies by leveraging novel NMTi payload technology to address treatment resistance in solid tumors.
The European Commission has officially approved Itvisma® as a new gene replacement therapy for patients with spinal muscular atrophy (SMA). This one-time treatment option is designed to address the underlying genetic cause of the disease in children two years and older, teens, and adults. The approval marks a significant development in the available therapeutic choices for those managing SMA across the European Union.
Novartis has announced promising results from the phase 3 RemIND trial, showing the potential of Rhapsido (remibrutinib) as a targeted therapy for chronic inducible urticaria (CIndU). The study demonstrated that the treatment provides significant symptom relief for patients, offering a new potential option for those whose condition remains inadequately controlled by standard antihistamines.
Novartis has announced promising results from the FORTITUDE Phase I/II clinical trial for del-brax, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD). This update underscores the ongoing commitment to advancing neurological science and finding potential disease-modifying therapies. Visitors to the Novartis Pavillon can learn more about how cutting-edge research and drug development are shaping the future of global healthcare.
Visual previews of the Novartis Pavillon in Basel highlight its striking contemporary architecture. Images show the unique dome-shaped building featuring a distinctive silver, diamond-patterned facade and glass entrance, surrounded by pathways and green trees. These photos capture the modern design and innovative spirit of this science exhibition space, inviting visitors to explore the interactive galleries inside.
Locate prestigious art institutions and heritage sites easily.
Streamline your search for cultural landmarks in Basel. Identify historical archives, fine art hubs, and scientific collections tailored to your specific curiosity. Access essential details for every venue to coordinate your upcoming visit.
